Participants 59 132 3
adults with autistic disorder and other pervasive developmental disorders
Participants 431 661 5
Thirty-one adults (age [mean+/-SD], 28.1+/-7.3 years) with autistic disorder (n=17) or pervasive developmental disorder not otherwise specified (n=14) participated in a 12-week double-blind, placebo-controlled trial of risperidone
